SUCCESSFUL IMPLEMENTATION OF COVERAGE WITH EVIDENCE DEVELOPMENT SCHEMES- PRACTICAL EXPERIENCES IN SEVERAL WESTERN JURISDICTIONS

Author(s)

Theunissen KA1, Delwel G2, Evers SM1, Goettsch W2, Severens H3, Hoomans T11Maastricht University, Maastricht, Limburg, Netherlands, 2Health Care Insurance Board (CVZ), Diemen, Netherlands, 3University Maastricht & Erasmus University Rotterdam, Maastricht, Netherlands

BACKGROUND: In Western jurisdictions, coverage with evidence development (CED) is seen as a promising scheme for linking coverage decisions on innovative health technologies with the generation of additional evidence. Nonetheless, the implementation of such CED schemes is not guaranteed to be successful, with issues arising around both evidence generation and (dis)continued coverage of technologies. OBJECTIVES: This qualitative study aims to explore the practical experiences with CED schemes for technology coverage. METHODS: Semi-structured interviews were conducted with key stakeholders involved in the decision making process about reimbursement of health technologies in Australia, Belgium, Ontario (Canada), France, Germany, Galicia (Spain), Sweden, UK and USA. The questionnaire for the interview was developed on the basis of comprehensive literature review and expert opinion, addressing issues related to the aim of CED, initial assessment/appraisal, evidence development, re-assessment/re-appraisal and coverage for technologies. RESULTS: CED schemes vary widely in the evidence generation, time frame, the regulation and funding of research, and the involvement of stakeholders in the CED process. This variation is caused by the structure and financing of health services delivery, the aim of CED, and the type of health technology. The CED process is often non-transparent, particularly relating to the selection of technologies and the re-assessment/re-appraisal for coverage (dis)continuation. (Dis)continued coverage of technologies is often primarily driven by the pressures from patients, health professional and health institutions to provide access to innovative technologies or public opinion. CONCLUSIONS:  The successful implementation of CED schemes requires: a) a transparent (analytic) framework for the selection of health technologies and the generation of additional evidence; b) a clear legal authority to regulate evidence generation, time frame and research budget; c) a structural involvement of stakeholders in the process of CED; and d) a priori clear end points for the re-assessment/re-appraisal and technology coverage.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PHP86

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Reimbursement & Access Policy

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×